A cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia

Clinical Infectious Diseases

Volumn 58, Issue 7, 2014, Pages 1027-1034

  Schneider, Karen ^a   Gray, Richard T ^a   Wilson, David P ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Cost effectiveness; HIV prevention; Men who have sex with men; Preexposure prophylaxis

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE COURSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFECTION PREVENTION; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEN WHO HAVE SEX WITH MEN; NEW SOUTH WALES; OUTCOME ASSESSMENT; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SEXUALITY; VIRUS TRANSMISSION; AUSTRALIA; CHEMOPROPHYLAXIS; COST; ECONOMICS; HIV INFECTIONS; MALE HOMOSEXUALITY; SERODIAGNOSIS; STATISTICAL MODEL; THEORETICAL MODEL; TRANSMISSION;

ANTI-HIV AGENTS; AUSTRALIA; CHEMOPREVENTION; COSTS AND COST ANALYSIS; HIV INFECTIONS; HIV SERONEGATIVITY; HOMOSEXUALITY, MALE; HUMANS; MALE; MEN; MODELS, ECONOMIC; MODELS, THEORETICAL;

EID: 84903959252     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit946     Document Type: Article

References (44)

1. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587-99.
2. Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399-410.
3. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423-34.
4. Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebocontrolled phase 3 trial. Lancet 2013; 381:2083-90.
5. World Health Organization. Guidance on preexposure oral prophylaxis (PrEP) for serodiscordant couples, men and transgender women who have sex with men at high risk of HIV: recommendations for use in the context of demonstration projects. Geneva, Switzerland: WHO, 2012.
6. Centers for Disease Control and Prevention. Update to interim guidance for preexposure prophylaxis (PrEP) for the prevention of HIV infection: PrEP for injecting drug users. Atlanta, Georgia: CDC, 2013.
7. Desai K, Sansom SL, Ackers ML, et al. Modeling the impact of HIV chemoprophylaxis strategies among men who have sex with men in the United States: HIV infections prevented and cost-effectiveness. AIDS 2008; 6:1829-39.
8. Paltiel AD, Freedberg KA, Scott CA, et al. HIV preexposure prophylaxis in the United States: impact on lifetime infection risk, clinical outcomes, and cost-effectiveness. Clin Infect Dis 2009; 48:806-15.
9. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2011. Sydney, Australia: The Kirby Institute, the University of New South Wales, 2011.
10. The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2012. Sydney, Australia: The Kirby Institute, the University of New South Wales, 2012.
11. Prestage G, Ferris J, Grierson J, et al. Homosexual men in Australia: population, distribution and HIV prevalence. Sex Health 2008; 5: 97-102.
12. National Centre in HIV Social Research. Sydney gay community periodic survey. Sydney, Australia: National Centre in HIV Social Research, University of New South Wales, 2012.
13. Gray RT, Ghaus MH, Hoare A, Wilson DP. Expected epidemiological impact of the introduction of a partially effective HIV vaccine among men who have sex with men in Australia. Vaccine 2011; 29:6125-9.
14. Gray RT, Prestage GP, Down I, et al. Increased HIV testing will modestly reduce HIV incidence among gay men in NSW and would be acceptable if HIV testing becomes convenient. PLoS One 2013; 8:e55449.
15. Wilson DP, Prestage G, Gray R, et al. NSW HIV modelling & acceptability project: effectiveness and acceptability of HIV interventions in NSW. Sydney, Australia: National Centre in HIV Epidemiology and Clinical Research, The University of New South Wales, 2011.
16. The Kirby Institute. Australian HIV Observational Database Annual Report. Sydney, Australia, 2012.
17. Hoare A, Kerr SJ, Ruxrungtham K, et al. Hidden drug resistant HIV to emerge in the era of universal treatment access in Southeast Asia. PLoS One 2010; 5:e10981.
18. Maggiolo F, Airoldi M, Kleinloog HD, et al. Effect of adherence to HAART on virologic outcome and on the selection of resistanceconferring mutations in NNRTI-or PI-treated patients. HIV Clin Trials 2007; 8:282-92.
19. Phillips A, Dunn D, Sabin C, et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice. AIDS 2005; 19:487.
20. Phillips AN, Leen C,Wilson A, et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study. Lancet 2007; 370:1923-8.
21. Albrecht D, Zöllner B, Feucht H-H, et al. Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy. J Clin Virol 2002; 24:93-8.
22. Ghosn J, Wirden M, Ktorza N, et al. No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients. AIDS 2005; 19:1643-7.
23. Brenner BG, Routy J-P, Petrella M, et al. Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection. J Virol 2002; 76:1753-61.
24. Ghosn J, Pellegrin I, Goujard C, et al. HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006; 20:159-70.
25. Blower S, Bodine E, Kahn J, McFarland W. The antiretroviral rollout and drug-resistant HIV in Africa: insights from empirical data and theoretical models. AIDS 2005; 19:1-14.
26. Blower S, Ma L, Farmer P, Koenig S. Predicting the impact of antiretrovirals in resource-poor settings: preventing HIV infections whilst controlling drug resistance. Curr Drug Targets Infect Disord 2003; 3:345-53.
27. Smith RJ, Okano JT, Kahn JS, Bodine EN, Blower S. Evolutionary dynamics of complex networks of HIV drug-resistant strains: the case of San Francisco. Science 2010; 327:697-701.
28. Tengs TO, Lin TH. A meta-analysis of utility estimates for HIV/AIDS. Med Decis Making 2002; 22:475-81.
29. Tsevat J, Sherman SN, McElwee JA, et al. The will to live among HIVinfected patients. Ann Intern Med 1999; 131:194-8.
30. Mrus JM, Yi MS, Freedberg KA, et al. Utilities derived from visual analog scale scores in patients with HIV/AIDS. Med Decis Making 2003; 23:414-21.
31. Freedberg KA, Scharfstein JA, Seage GR, et al. The cost-effectiveness of preventing AIDS-related opportunistic infections. JAMA 1998; 14: 130-6.
32. Schackman BR, Goldie SJ, Freedberg KA, Losina E, Brazier J,Weinstein MC. Comparison of health state utilities using community and patient preference weights derived from a survey of patients with HIV/AIDS. Med Decis Making 2002; 22:27-38.
33. Kahn JO, Walker BD. Acute human immunodeficiency virus type 1 infection. N Engl J Med 1998; 339:33-9.
34. Holt M, Murphy DA, Callander D, et al. Willingness to use HIV preexposure prophylaxis and the likelihood of decreased condom use are both associated with unprotected anal intercourse and the perceived likelihood of becoming HIV positive among Australian gay and bisexual men. Sex Transm Infect 2012; 88:258-63.
35. Zablotska IB, Prestage G, de Wit J, Grulich AE, Mao L, Holt M. The informal use of antiretrovirals for preexposure prophylaxis of HIV infection among gay men in Australia. J Acquir Immune Defic Syndr 2013; 62:334-8.
36. Grohskopf L, Gvetadze R, Pathak S, et al. Preliminary analysis of biomedical data from the phase II clinical safety trial of tenofovir disoproxil fumarate (TDF) for HIV-1 pre-exposure prophylaxis (PrEP) among U.S. men who have sex with men (MSM). In: XVIII International AIDS Conference, Vienna, Austria, 2010.
37. Abdool Karim Q, Abdool Karim SS, Frohlich JA, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329: 1168-74.
38. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. Morbidity and Mortality Weekly Report (MMWR). Atlanta, Georgia: CDC, 2011. Available at: http://www.cdc.gov/mmwr/ preview/mmwrhtml/mm6003a1.htm?s-cid=mm6003a1-w. Accessed 2 February 2013.
39. The Department of Heath, Australian Government. Pharmaceutical benefits scheme, tenofovir +emtricitabine. Available at: http://www. pbs.gov.au/medicine/item/6468k. Accessed 2 February 2013.
40. The Department of Heath, Australian Government. Pharmaceutical benefits scheme. Available at: http://www.pbs.gov.au. Accessed 2 February 2013.
41. The Department of Heath, Australian Government. Medicare benefits schedule. Available at: http://www.health.gov.au/internet/mbsonline/ publishing.nsf/Content/Medicare-Benefits-Schedule-MBS-1. Accessed 2 February 2013.
42. The Department of Heath, Australian Government. National public cost weight tables. Round 14. Available at: http://www.health.gov.au/ internet/main/publishing.nsf/Content/health-casemix-data-collectionsabout. Accessed 2 February 2013.
43. Myers GM, Mayer KH. Oral preexposure anti-HIV prophylaxis for high-risk U.S. populations: current considerations in light of new findings. AIDS Patient Care STDS 2011; 25:63-71.
44. Mansergh G, Koblin BA, Sullivan PS. Challenges for HIV pre-exposure prophylaxis among men who have sex with men in the United States. PLoS Med 2012; 9:e1001286.